Introduction: A Long-Standing Question in Colon Cancer Care
For many patients with colon cancer, the usual sequence of treatment is straightforward: operate first, then decide whether chemotherapy is needed based on what the surgeon and pathologist find. But in recent years, oncologists have been asking a reasonable question: what if some patients would do better by starting chemotherapy before surgery instead?
That strategy is called neoadjuvant chemotherapy. It is already common in several cancers, including breast, rectal, and some stomach cancers. The idea is appealing. Treat the tumor early, shrink it if possible, attack microscopic disease sooner, and perhaps make surgery easier or reduce the need for more chemotherapy afterward.
A newly published randomized phase III trial, NeoCol, directly tested this idea in locally advanced colon cancer. Its answer was not a simple yes or no. The trial was officially negative because chemotherapy before surgery did not improve disease-free survival compared with standard upfront surgery. But the details matter. The treatment was feasible, reasonably safe, did shrink tumors, and reduced the number of patients who later met criteria for adjuvant chemotherapy. It also raised an especially important biological clue: patients with mismatch repair-deficient tumors may behave differently.
For patients, clinicians, and researchers, this is exactly the kind of study that changes the conversation even when it does not change the standard of care overnight.
What Is Locally Advanced Colon Cancer?
Colon cancer is often staged by how deeply the tumor has grown into the bowel wall, whether lymph nodes are involved, and whether it has spread elsewhere. “Locally advanced” generally refers to tumors that appear, on imaging, to have grown deeply through the colon wall or into nearby tissues, with a higher risk of recurrence even when no distant metastases are visible.
These patients are challenging because preoperative CT scans do not always predict final pathology perfectly. Some tumors thought to be very advanced turn out to be less extensive after surgery, while others behave aggressively despite apparently localized disease.
That uncertainty is one reason treatment sequencing matters. If a patient is likely to need chemotherapy anyway, starting it before surgery may offer advantages. But if many patients can already be cured with surgery first, moving chemotherapy earlier must show clear benefit to justify the change.
The NeoCol Trial: What Was Studied?
The NeoCol trial enrolled 250 patients in Denmark, Norway, and Sweden between 2013 and 2020. Eligible patients had CT-staged locally advanced colon cancer, good enough performance status to receive treatment, and no distant metastases.
Patients were randomly assigned to one of two approaches:
| Study Arm | Treatment Strategy |
|---|---|
| Upfront surgery | Surgery first, followed by adjuvant chemotherapy if indicated |
| Neoadjuvant chemotherapy | 3 cycles of capecitabine plus oxaliplatin before surgery, then adjuvant chemotherapy if indicated |
The main outcome was disease-free survival at 3 years, a common measure that asks whether a patient is alive without cancer recurrence or a new cancer event.
Among 248 eligible patients included in analysis, the 3-year disease-free survival rate was 87% in the upfront surgery group and 83% in the neoadjuvant group. Statistically, this was not a significant difference.
In plain language: giving chemotherapy before surgery did not improve the trial’s primary endpoint.
Why This “Negative” Trial Still Matters
In medicine, “negative” does not mean “useless.” It means the main hypothesis was not confirmed. NeoCol still offers several clinically meaningful findings.
First, preoperative chemotherapy was feasible. Patients were generally able to receive treatment and proceed to surgery.
Second, it appeared safe. Postoperative complications, adverse events, and quality-of-life measures were comparable between groups.
Third, it produced tumor downstaging. That means the cancer often looked less advanced at surgery and under the microscope after preoperative treatment.
Fourth, fewer patients in the neoadjuvant group met criteria for postoperative adjuvant chemotherapy: 59% versus 73% in the upfront surgery group. That could matter to patients who want to reduce cumulative treatment burden, although whether this translates into better long-term outcomes remains uncertain.
These findings suggest that neoadjuvant chemotherapy is not a reckless strategy in carefully selected patients. It simply has not yet proven superior as a routine default approach for all patients with locally advanced colon cancer.
A Fictional Patient Story: Michael’s Decision
Michael, a 64-year-old accountant, is told that his CT scan shows a bulky colon tumor that may extend beyond the bowel wall. His surgeon says the standard plan is surgery first. His medical oncologist explains that some centers also consider chemotherapy before surgery in selected cases, especially in clinical trials.
Michael asks the question many patients ask: “If chemo can shrink the cancer, why not start now?”
The answer is nuanced. Starting chemotherapy early might shrink the tumor and treat invisible cancer cells sooner. But it also delays surgery, exposes the patient to drug toxicity upfront, and, according to the best randomized evidence so far, has not clearly improved disease-free survival across all patients.
For Michael, the decision would depend on the details: how threatening the tumor looks on imaging, whether it seems technically resectable, whether he has symptoms such as obstruction, and what the tumor’s molecular profile shows. The new evidence does not eliminate judgment. It makes that judgment better informed.
The Mismatch Repair Question: A Major Clue for Personalized Care
One of the most interesting parts of NeoCol was its exploratory analysis by mismatch repair, or MMR, status.
MMR is a DNA repair system. Tumors that are mismatch repair-deficient, often abbreviated dMMR, accumulate many mutations and have distinct biology. These cancers are important because they can behave differently and may respond differently to therapy.
In NeoCol, exploratory findings suggested higher disease-free survival after upfront surgery among patients with dMMR tumors. Because this was not the primary endpoint and the subgroup was relatively small, it should not be overinterpreted. Still, it fits a broader body of evidence suggesting that dMMR colon cancers may benefit less from conventional fluoropyrimidine-based chemotherapy than MMR-proficient tumors.
This matters because the neoadjuvant regimen used in NeoCol was capecitabine and oxaliplatin, a fluoropyrimidine-based combination. If a subgroup is intrinsically less sensitive to that approach, then giving it earlier may not help.
This is where modern oncology is heading: not just asking whether a treatment works, but asking for whom it works.
How NeoCol Fits With Earlier Evidence
NeoCol does not stand alone. The most influential previous randomized study in this space has been the FOxTROT program, which also evaluated preoperative chemotherapy for locally advanced colon cancer.
FOxTROT showed that neoadjuvant chemotherapy could be delivered safely, led to pathological downstaging, and reduced incomplete resections, strengthening the case that the strategy is biologically active and surgically practical. But, as with NeoCol, the key challenge is whether those short-term gains translate into meaningful long-term survival benefits for broad patient populations.
Taken together, the evidence suggests three conclusions:
1. Neoadjuvant chemotherapy for colon cancer is possible.
2. It can improve some intermediate outcomes, such as downstaging.
3. It has not yet clearly proven a disease-free or overall survival advantage for all-comers.
That is a very different message from saying the strategy failed completely.
Common Misconceptions Patients Should Avoid
A study like NeoCol can easily be misunderstood. Here are several common mistakes in interpretation.
First misconception: “Chemotherapy before surgery does not work.”
That is too simplistic. The trial showed no disease-free survival benefit overall, but it did show tumor downstaging and acceptable safety.
Second misconception: “If the tumor shrinks, patients must live longer.”
Not necessarily. Short-term radiologic or pathologic improvements do not always translate into better long-term outcomes.
Third misconception: “All colon cancers should be treated the same way.”
Modern cancer care is increasingly molecular. MMR status, and likely other biomarkers in the future, can influence the value of treatment strategies.
Fourth misconception: “A negative trial means the idea should be abandoned.”
Often the opposite is true. Negative trials refine treatment selection and help identify which patients should not receive a given therapy routinely.
What Patients Should Ask Their Care Team
If you or a loved one has newly diagnosed locally advanced colon cancer, practical questions matter more than abstract debate. Useful questions include:
What stage do you think this is based on imaging, and how confident are you?
Will surgery likely be straightforward, or does the tumor look bulky or high-risk?
Has the tumor been tested for mismatch repair deficiency or microsatellite instability?
Would chemotherapy before surgery offer any specific advantage in my case?
Am I a candidate for a clinical trial?
If we do surgery first, what are the chances I will need chemotherapy afterward?
Patients should also know that colon cancer is not the same as rectal cancer. In rectal cancer, preoperative therapy is far more established. Media headlines can blur this distinction, but clinicians should not.
What This Means for Current Practice
For now, upfront surgery remains the standard approach for most resectable locally advanced colon cancers outside selected multidisciplinary settings or clinical trials.
However, NeoCol supports the idea that neoadjuvant chemotherapy can be considered in carefully chosen patients, particularly where tumor bulk, local extent, or treatment planning raises concern. It also reinforces the importance of high-quality imaging, multidisciplinary discussion, and molecular profiling.
In practical terms, the study pushes the field toward a more individualized framework:
| Clinical Question | Current Takeaway |
|---|---|
| Should all patients receive chemotherapy before surgery? | No. The new trial does not support routine use for everyone. |
| Is preoperative chemotherapy safe and feasible? | Generally yes, in appropriate patients and experienced centers. |
| Does it shrink tumors? | Yes, downstaging was observed. |
| Does it improve 3-year disease-free survival overall? | Not in NeoCol. |
| Could biomarkers matter? | Very likely. MMR status appears especially relevant. |
The Bigger Trend: Precision Oncology, Not One-Size-Fits-All Oncology
The most important lesson from NeoCol may be philosophical rather than procedural. Cancer care is moving away from “one treatment sequence fits all” and toward risk-adapted, biomarker-informed planning.
That trend is visible across oncology. Some tumors need early systemic therapy. Some are best treated by prompt surgery. Some respond dramatically to immunotherapy because of their molecular profile. Others do not. The future of colon cancer care will probably involve more precise selection using imaging, pathology, circulating tumor DNA, and genomic markers.
It is also possible that chemotherapy is not the ultimate preoperative strategy for every biologic subtype. For example, dMMR colon cancers may eventually be better served by approaches that leverage their immune sensitivity, though that remains an area of active investigation and should not yet be generalized beyond evidence.
Bottom Line
The NeoCol trial delivers a careful but important message. Chemotherapy before surgery for locally advanced colon cancer did not improve 3-year disease-free survival compared with standard surgery-first care. That means it should not become routine for all patients based on current evidence.
But the story does not end there. The strategy was feasible, safe, and biologically active. It downstaged tumors and reduced the proportion of patients needing postoperative chemotherapy. Most importantly, the trial highlighted that tumor biology, especially mismatch repair status, may influence which patients benefit and which do not.
For patients, that means treatment decisions should be individualized, not rushed, and ideally discussed in a multidisciplinary setting. For clinicians and researchers, NeoCol is less a dead end than a signpost: the next advances in colon cancer may come not from treating everyone earlier, but from treating the right patients earlier.
References
1. Jensen LH, Kjaer M, Diness LV, et al. Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical Trial. JAMA Surgery. 2026;161(5):450-458. PMID: 41779406.
2. Seymour MT, Morton D; on behalf of the International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1052 patients evaluating neoadjuvant chemotherapy for colon cancer. Lancet Oncology. 2023;24(6):673-685.
3. Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(10):1291-1305.
4. Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2021;19(3):329-359.
5. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New England Journal of Medicine. 2003;349(3):247-257.
6. André T, de Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. Journal of Clinical Oncology. 2015;33(35):4176-4187.
